Search | Médecins Sans Frontières Access Campaign

About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action!

GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017.

Photo credit: Borja Ruiz Rodriguez/MSF

Time for $5

The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.

13 results found
There is 1 active filter
Clear all filters
Spotlight

13 results found

Covid-19 Vaccine Equitable Access - Public Good

Spotlight |

26 April 2021

COVID-19 vaccines: Recommendations for equitable access

Governments and philanthropies have contributed billions to the research and development of COVID-19 vaccines, heads of state spoke about making the vaccines “global public goods”, and the COVAX Facility was launched to deliver COVID ...

Tags COVID-19 coronavirus covid medical tools access

podb-square-poster

Spotlight |

05 October 2020

Patent Oppositions Database

The Patent Opposition Database is a project of the Médecins Sans Frontières Access Campaign. It provides support and resources for those wanting to challenge patents on medicines. It was created under a UNITAID grant in support of the endTB project.

Covid-19 Vaccine Equitable Access - Public Good

Spotlight |

22 June 2020

COVID-19 vaccine: 6 recommendations for equitable access

Heads of state have talked about making future COVID-19 vaccines ‘global public goods’. But what does that mean in practice?

Tags COVID-19 coronavirus Gavi, the Vaccine Alliance covid medical tools access

Hospital instalado por Medicos Sin Fronteras para tratar enfermos de coronavirus en Leganes.

Spotlight |

07 May 2020

COVID-19: Crisis update

COVID-19 is a disease caused by a contagious new coronavirus, SARS-CoV-2, and everyone is at risk of being infected. Health workers are on the frontline of the response to the pandemic and their protection is vital to ensure that ...

Tags COVID-19 coronavirus

Drug Pricing Transparency - Big Pharma

Spotlight |

15 February 2020

How Big Pharma is making people pay twice for many of the medicines they buy

Let’s try to explain all the ways that pharma is… double-dipping in taxpayers’ pockets for the medicines they sell us.

Tags Research and development

Access to Affordable Medicines

Spotlight |

15 February 2020

Access to affordable medicines is a growing global challenge: Europe is no exception

Access to affordable medicines is a growing global challenge: Europe is no exception

Tags Intellectual property and tradeResearch and development

Snakebite Treatment

Spotlight |

07 August 2018

Spotlight on: Snakebite

This is the real-life nightmare for 100,000+ people killed by snakebite every year and 400,000 more that are left with life-changing disabilities.

Tags Tropical & neglected diseases snakebite antivenom access to medicinesresearch and development (R&D)substandard & counterfeit medicinestropical medicineWHO pre-qualification Health Action InternationalWorld Health Organization

Chagas treatment

Spotlight

Spotlight on: USFDA neglected disease PRV

Tags Intellectual property and trade Chagas diseasevisceral leishmaniasis (kala azar)Zika FDA priority review voucher

Metro advertisements for Doctors Without Borders in Washington DC, 2015.

Spotlight

Spotlight on: Trans-Pacific Partnership Agreement

Tags Intellectual property and trade Trans-Pacific Partnership Agreement (TPP)

Civil society demonstration against IP provisions in RCEP that can block access to affordable medicines during the 6th round of negotiations. 3rd December 2014

Spotlight

Spotlight on: Regional Comprehensive Economic Partnership (RCEP)

The Regional Comprehensive Economic Partnership (RCEP) trade agreement includes provisions that threaten access to medicines

Tags Intellectual property and trade Regional Comprehensive Economic Partnership (RCEP)

HIV_Mozambique_pills_AndreFrancois_2012_MSF124560

Spotlight

Spotlight on: TRIPS, TRIPS Plus, and Doha

Spotlight on: TRIPS, TRIPS Plus, and Doha

Tags Intellectual property and trade Doha DeclarationTRIPS

A protest was organised by Indian civil society on World AIDS Day, 1 December 2011, in front of Novartis' Mumbai Office.

Spotlight

Affordable medicines from India under attack: What’s at stake

People, Before Profits: India’s Patent Law Under Attack

Tags Intellectual property and trade #HandsOffOurMeds

Substandard or counterfeit medicines

Spotlight

Spotlight on: Substandard & Counterfeit Medicines

Tags Intellectual property and trade Anti-Counterfeiting Trade Agreement (ACTA)substandard & counterfeit medicines